200 related articles for article (PubMed ID: 10845810)
1. Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene.
Hellmann-Blumberg U; Taras TL; Wurz GT; DeGregorio MW
Breast Cancer Res Treat; 2000 Mar; 60(1):63-70. PubMed ID: 10845810
[TBL] [Abstract][Full Text] [Related]
2. Induction of hepatic aneuploidy in vivo by tamoxifen, toremifene and idoxifene in female Sprague-Dawley rats.
Sargent LM; Dragan YP; Sattler C; Bahnub N; Sattler G; Martin P; Cisneros A; Mann J; Thorgeirsson S; Jordan VC; Pitot HC
Carcinogenesis; 1996 May; 17(5):1051-6. PubMed ID: 8640912
[TBL] [Abstract][Full Text] [Related]
3. DNA adduct formation in the livers of female Sprague-Dawley rats treated with toremifene or alpha-hydroxytoremifene.
Gamboa da Costa G; Pereira PC; Churchwell MI; Beland FA; Marques MM
Chem Res Toxicol; 2007 Feb; 20(2):300-10. PubMed ID: 17261033
[TBL] [Abstract][Full Text] [Related]
4. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats.
Hard GC; Iatropoulos MJ; Jordan K; Radi L; Kaltenberg OP; Imondi AR; Williams GM
Cancer Res; 1993 Oct; 53(19):4534-41. PubMed ID: 8402624
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of lower genotoxicity of toremifene compared with tamoxifen.
Shibutani S; Ravindernath A; Terashima I; Suzuki N; Laxmi YR; Kanno Y; Suzuki M; Apak TI; Sheng JJ; Duffel MW
Cancer Res; 2001 May; 61(10):3925-31. PubMed ID: 11358807
[TBL] [Abstract][Full Text] [Related]
6. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells.
White IN; de Matteis F; Davies A; Smith LL; Crofton-Sleigh C; Venitt S; Hewer A; Phillips DH
Carcinogenesis; 1992 Dec; 13(12):2197-203. PubMed ID: 1473224
[TBL] [Abstract][Full Text] [Related]
7. Intrinsic reactivity of tamoxifen and toremifene metabolites with DNA.
Hellmann-Blumberg U; Cartner MG; Wurz GT; DeGregorio MW
Breast Cancer Res Treat; 1998 Jul; 50(2):135-41. PubMed ID: 9822218
[TBL] [Abstract][Full Text] [Related]
8. Absence of DNA adduct in the leukocytes from breast cancer patients treated with toremifene.
Umemoto A; Lin CX; Ueyama Y; Komaki K; Santosh Laxmi YR; Shibutani S
Chem Res Toxicol; 2006 Mar; 19(3):421-5. PubMed ID: 16544947
[TBL] [Abstract][Full Text] [Related]
9. Determination of tamoxifen--DNA adducts in leukocytes from breast cancer patients treated with tamoxifen.
Umemoto A; Monden Y; Lin CX; Abdul-Momen M; Ueyama Y; Komaki K; Laxmi YR; Shibutani S
Chem Res Toxicol; 2004 Dec; 17(12):1577-83. PubMed ID: 15606132
[TBL] [Abstract][Full Text] [Related]
10. Comparison of DNA reactivity of the polyphenylethylene hormonal agents diethylstilbestrol, tamoxifen and toremifene in rat and hamster liver.
Montandon F; Williams GM
Arch Toxicol; 1994; 68(4):272-5. PubMed ID: 8067901
[TBL] [Abstract][Full Text] [Related]
11. Formation of tamoxifen-DNA adducts in multiple organs of adult female cynomolgus monkeys dosed with tamoxifen for 30 days.
Schild LJ; Divi RL; Beland FA; Churchwell MI; Doerge DR; Gamboa da Costa G; Marques MM; Poirier MC
Cancer Res; 2003 Sep; 63(18):5999-6003. PubMed ID: 14522927
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer.
Taras TL; Wurz GT; DeGregorio MW
J Steroid Biochem Mol Biol; 2001 Jun; 77(4-5):271-9. PubMed ID: 11457665
[TBL] [Abstract][Full Text] [Related]
13. Delayed effects of tamoxifen in hepatocarcinogenesis-resistant Fischer 344 rats as compared with susceptible strains.
Stanley LA; Carthew P; Davies R; Higginson F; Martin E; Styles JA
Cancer Lett; 2001 Sep; 171(1):27-35. PubMed ID: 11485825
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen: evidence by 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite.
Randerath K; Moorthy B; Mabon N; Sriram P
Carcinogenesis; 1994 Oct; 15(10):2087-94. PubMed ID: 7955037
[TBL] [Abstract][Full Text] [Related]
15. Toxicity of antiestrogens.
Hirsimäki P; Aaltonen A; Mäntylä E
Breast J; 2002; 8(2):92-6. PubMed ID: 11896754
[TBL] [Abstract][Full Text] [Related]
16. Lack of evidence for tamoxifen- and toremifene-DNA adducts in lymphocytes of treated patients.
Bartsch H; Phillips DH; Nair J; Hewer A; Meyberg-Solomeyer G; Grischke EM
Carcinogenesis; 2000 Apr; 21(4):845-7. PubMed ID: 10753226
[TBL] [Abstract][Full Text] [Related]
17. Electrospray ionization-tandem mass spectrometry and 32P-postlabeling analyses of tamoxifen-DNA adducts in humans.
Beland FA; Churchwell MI; Doerge DR; Parkin DR; Malejka-Giganti D; Hewer A; Phillips DH; Carmichael PL; Gamboa da Costa G; Marques MM
J Natl Cancer Inst; 2004 Jul; 96(14):1099-104. PubMed ID: 15265972
[TBL] [Abstract][Full Text] [Related]
18. [Assessment of post-administration body distribution of toremifene and tamoxifen, and their administration regimens].
Masuoka H; Mori M; Nomura N; Sakurai M; Yoshida K; Usuda N; Shirai H; Shimokawara I; Asaishi K
Gan To Kagaku Ryoho; 2002 Jun; 29(6):881-7. PubMed ID: 12090039
[TBL] [Abstract][Full Text] [Related]
19. 4-Hydroxylated metabolites of the antiestrogens tamoxifen and toremifene are metabolized to unusually stable quinone methides.
Fan PW; Zhang F; Bolton JL
Chem Res Toxicol; 2000 Jan; 13(1):45-52. PubMed ID: 10649966
[TBL] [Abstract][Full Text] [Related]
20. Genotoxicity studies with the antiestrogen toremifene.
Williams GM; Ross PM; Jeffrey AM; Karlsson S
Drug Chem Toxicol; 1998 Nov; 21(4):449-76. PubMed ID: 9839155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
